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Aims Patients at riskof pulmonary arterial hypertension (PAH)may presentwith abnormal dynamic pulmonary vascular resist-
ance (PVR) during exercise. However, its clinical significance remains unclear. The present study aimed at analysing the




Adult patients with corrected ASD were consecutively selected from the database of Pediatric and Congenital Heart
Disease of the University Hospitals Leuven. Patients with SSc were consecutively selected from the rheumatology data-
base of the University Hospital Lie`ge. At inclusion, all underwent a rest and bicycle stress echocardiography to obtain
baseline right heart characteristics and dynamic PVR. Routine follow-up echocardiography was performed. Twenty-
eight patients with corrected ASD (mean age 41+ 17 years, 79% female) were followed for a median time of 3.7
[inter-quartile range (IQR) 2.9–4.1] years. No patient developed PAH. Dynamic PVR was significantly associated with
right atrial dilatation at latest follow-up (Spearman’s r 0.51, P ¼ 0.013). Forty-five SSc patients (mean age 54+13
years, 76% female) were followed for a median time of 2.4 (IQR 0.8–2.9) years. Thirteen patients (30%) developed
PAH. Dynamic PVR was the only independent predictor of PAH (hazards ratio 1.22, 95% confidence interval 1.01–
1.47). No significant right heart morphometric changes occurred.
Conclusion Dynamic PVR predicted PAH development in patients with SSc, whereas dynamic PVR was associated with right heart
morphometric changes after ASD closure. The predictive role of dynamic PVR might depend on the underlying
disease type. Larger studies are needed to confirm this hypothesis.
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Introduction
Pulmonary arterial hypertension (PAH), characterized by a progres-
sive increase in pulmonary vascular resistance (PVR), is associated
with considerable morbidity and mortality.1 Unfortunately, PAH is
usually detected when patients develop symptoms and pulmonary
vascular disease (PVD) has already evolved to an advanced (irrevers-
ible) stage.2,3 Hence, treatment is often initiated too late, and results
are unsatisfactory. Therefore, developing an early detection method
for mild PVD is crucially important.
In the last years, many studies have demonstrated an abnormal in-
crease in pulmonary artery pressure (PAP) and/or PVR during exer-
cise testing in different populations at risk of PAH development.4–12
This so-called exercise-induced PAH has been associated with
decreased oxygen uptake during exercise and impaired exercise
capacity.13–15 It has been suggested that the slope of a PAP-flow
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plot, defining dynamic PVR, provides a better representation of
PVR.16 However, the clinical significance of dynamic PVR remains
unclear. Does a high-dynamic PVR represent a stable self-contained
entity or could it equal an early stage in the ‘disease spectrum of
PAH’?14,15,17
The aetiology of PVD is very diverse and explains why the pace of
disease progression might differ substantially between several types
of PVD. Idiopathic PVD and PVD associated with connective tissue
disease usually evolve fast, whereas PVD secondary to shunt-related
congenital heart disease (CHD) is mostly avoided in case of early
closure of septal defects in childhood.1,18,19 However, after paediat-
ric age, there is no evidence that closure of septal defects can prevent
PVD progression, and prognosis may even be worsened by late
closure.20 This different pace of PVD progression might lead to a dif-
ferent predictive role of dynamic PVR.
This study aimed at determining the significance of dynamic PVR in
two populations at risk of developing PAH: patients with secundum
atrial septal defect (ASD), mostly closed later in life, and patients
with systemic sclerosis (SSc).
Methods
Patient selection
Patients with secundum ASD closure were consecutively selected from
the database of Pediatric and Congenital Heart Disease of the University
Hospitals Leuven fromMarch toNovember 2009. Minimum age at inclu-
sion was 18 years, and patients had to be able to perform a bicycle stress
test. Patients with associated complex diseases (coronary artery disease,
significant valvular diseases other than mild tricuspid or mitral regurgita-
tion, pulmonary disease, history of pulmonary embolism, concomitant
CHD) were excluded. Patients with a history of arrhythmias or current
arrhythmias were also excluded because of practical and safety reasons.
Similarly, patients with SSc were consecutively selected from the rheuma-
tology database of the University Hospital of Lie`ge from January 2008 to
November 2012.21 All patients signed informed consent, after theUniver-
sity Hospitals Institutional Review Boards approved the study protocol.
Rest and bicycle stress echocardiography
At inclusion, all patients underwent complete transthoracic echocardio-
graphic exam at rest in the supine position, followed by bicycle stress
echocardiography in semi-supine position. For the ASD group, a Vivid
7 or 9 ultrasound system (General Electric Vingmed Ultrasound,
Horten, Norway), for the SSc group a Vivid 9 ultrasound system
(General Electric Healthcare, Little Chalfont, UK), was used. Methodo-
logical details and baseline characteristics have already been pub-
lished.6,21 Bicycle stress echocardiography was performed in a
semi-supine position, with the exercise table tilted 20–308 to the left.
Patients started at an initial workload of 25W, which was increased by
25W every 2 min, until the maximal tolerated workload. A 12-lead
ECG and blood pressure were recorded at rest and at every 2 min
during exercise. Analyseswere performed by a single observer using cus-
tomized software (Echopac). All measurements were calculated in tripli-
cate and presented as means. Measurements were performed and
analysed according to the 2006 guidelines on chamber quantification.22
Basic echocardiogram mainly focused on right heart geometry [right
atrial (RA) diameter, right ventricular (RV) diameter, grade of tricuspid
valve regurgitation (TR)] and tricuspid regurgitation velocity (TRV),
from which the pressure difference between RV and RA was calculated
using the simplified Bernoulli equation. Adding RA pressure (RAP)
resulted in the estimate of systolic PAP (sPAP). RAP was calculated
from diameter and breath-induced variability of inferior vena cava
(IVC). For all patients, due to normal IVC diameter and decrease in
IVC diameter .50% after deep inspiration, RAP was estimated at
5 mmHg at rest and at 10 mmHg at peak exercise, similar to themethod-
ology of other studies.13,17,23–25
Total PVR was calculated as the ratio of sPAP and left ventricular
cardiac output (flow, calculated from the velocity time integral in the
left ventricular outflow tract), at rest and at peak exercise. The slope of
the sPAP-flow plot was obtained and determined as dynamic PVR,
using linear regression analysis with two measurement points (rest and
peak exercise). Dynamic PVR thus represents change in sPAP per unit
change in cardiac output from rest to peak exercise.
RA and RV dilatation was graded normal (0/3), mild (1/3), moderate
(2/3) or severe (3/3), based on measurements in apical four-chamber
view (RA: long-axis diameter and area at end-systole; RV: short-axis diam-
eter at themid-ventricular level and area at end-diastole).22 TRwas graded
semi-quantitatively using colour Doppler echocardiography (x/4).26
Follow-up
All patients were followed systematically. Rest transthoracic echocardio-
gramat latest follow-upwasconsidered the studyendpoint,with focuson
right heart geometry and the presence of PAH. RA and RV change were
graded (0 ¼ no increase in dilatation grade, 1 ¼ increase in dilatationof 1
grade, 2 ¼ increase in dilatationof 2 grades). TRchangewasdefined simi-
larly based on the increase in regurgitation grade. PAH at rest was diag-
nosed when estimated sPAP ≥37 mmHg (TRV ≥2.9 m/s + RAP
5 mmHg), following ESC/ERS guidelines on pulmonary hypertension.1
Statistical analysis
Statistical analyses were performed using the software program SPSS
(version 22.0, Chicago, IL, USA). For continuous variables, data are
reported as means+ standard deviation, or as medians [inter-quartile
range (IQR)] if the assumption of normal distribution was not valid.
Levene’s test was performed to assess for equal variances. Discrete vari-
ables are presented as frequencies and/or proportions. Comparison of
two means was done by two-tailed Student’s t-test. Analysis of paired
datawas done by two-tailed paired Student’s t-test or by related-samples
Wilcoxon signed-rank test, when normality was not assumed. Compari-
son of severalmeanswas done by one-way analysis of variance. Pearson’s
correlation coefficient and Spearman’s rank correlation coefficient were
calculated to estimate the correlation between dynamic PVR and PAP
or right heart morphometry, respectively. Univariate and multivariate
Cox-regression analysiswas performed to identify predictors of PAHde-
velopment.Only those factors that are significant predictors in univariate
analysiswill be included inmultivariate analysis. In caseof strong collinear-
ity (r . 0.5), onlyoneof the collinear variableswas retained formultivari-




Twenty-eight patients with corrected ASD (mean age at inclusion
41+17 years, 79% female patients) were selected and followed
for a median time of 3.7 (IQR 2.9–4.1) years. Forty-five patients
with SSc (mean age at inclusion 54+ 13 years, 76% female patients)
were selected and followed for a median time of 2.4 (IQR 0.8–2.9)
years. Patient baseline characteristics are summarized in Table 1.
None of the patients died during follow-up.
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Dynamic PVR in patients with corrected
ASD: associatedmorphometric changesof
the right heart
Mean dynamic PVR was 5.6+2.4 mmHg/L/min. No patient devel-
oped PAH during follow-up. RA diameter and TR severity evolved
significantly during follow-up (Table 2).
Dynamic PVR was only associated with greater RA dilatation
grade at latest follow-up, and a trend towards association with RA
change over time was noted (Table 3). RA dilated significantly more
during follow-up in patients with higher dynamic PVR at inclusion
(mean dynamic PVR 5.2+2.1 vs. 6.8+2.7 vs. 10.8 mmHg/L/min,
P ¼ 0.047) (Figure 1).
Dynamic PVR in patients with SSc:
predictor of PAH
Mean dynamic PVR was 7.3+4.2 mmHg/L/min. Thirteen patients
(30%) developed PAH during follow-up. No morphometric
changes of the right heart were noted.
Dynamic PVR, age at latest follow-up, sPAP at rest and sPAP and
total PVR at peak exercisewere significantly associatedwith PAHde-
velopment (Table 4). Patients with higher dynamic PVR (steeper
slopes) and a higher sPAP at rest developed PAH. Because bivariate
correlation analysis showed a strong correlation between dynamic
PVR and sPAP at peak exercise (Pearson’s correlation coefficient
0.595, P ¼ 0.001) and between dynamic PVR and total PVR at peak
exercise (Pearson’s correlation coefficient 0.862, P, 0.001), sPAP
and total PVR at peak exercise were excluded from the multivariate
model. Multivariate Cox-regression analysis showed that dynamic
PVR was the only independent predictor of PAH (Table 4). Mean
dynamic PVR in the PAH group was significantly higher than in the
non-PAH group (11.0 vs. 5.8 mmHg/L/min, P ¼ 0.002).
Comparison between both populations
Patients with SSc and corrected ASD were divided based upon
the development of PAH or RA change over time, respectively
(Figure 2). Whereas mean dynamic PVR differed significantly in the
PAH vs. non-PAH group of SSc patients (P ¼ 0.002) and in the
group of corrected ASD patients with vs. without RA change (7.6
vs. 5.1 mmHg/L/min, P ¼ 0.042), there was no significant difference
in mean dynamic PVR of SSc patients with PAH vs. corrected ASD
patients with RA change (P ¼ 0.144). Likewise, mean dynamic PVR
of SSc patients without PAH vs. corrected ASD patients without
RA change did not differ significantly (P ¼ 0.487). This is visually
represented in Figure 3.
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Age at inclusion (years) 41+17 54+13
Age at SSc diagnosis (years) 49+15
Age at ASD closure (years) 34+20
ASD defect size (mm) 17+5
Shunt ratio prior to ASD
closure (Qp : Qs)a
1.9 (1.5–2.5)
sPAP prior to ASD closure
(mmHg)a
26+8
Gender (male : female) 6 : 22 11 : 34
BMI (kg/m2) 26+5 24+5
SBP rest (mmHg) 119+16 131+22
DBP rest (mmHg) 71+11 75+11
HR rest (bpm) 63+10 73+13
RA dilatation (x/3) 0 (0–0) 0 (0–0)
RV dilatation (x/3) 0 (0–1) 0 (0–0)
TR (x/4) 1 (0–1.5) 1 (0–1)
sPAP rest (mmHg) 27+6 25+7
Total PVR rest (mmHg/L/min) 6.3+1.7 6.9+2.4
Total PVR peak exercise
(mmHg/L/min)
5.8+1.6 6.5+2.5
Continuous variables are presented as mean+ standard deviation, discrete
variables as ratio or as median (inter-quartile range).
ASD, atrial septal defect; SSc, systemic sclerosis; BMI, body mass index; SBP, systolic
blood pressure; DBP, diastolic blood pressure; HR, heart rate; RA, right atrium; RV,
right ventricle; TR, tricuspid regurgitation; sPAP, systolic pulmonary artery pressure;
PVR, pulmonary vascular resistance.
aInvasive measurement.
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Table 2 Changes in echocardiographic variables of the
corrected ASD group
Baseline Latest follow-up P-value
RA diameter (mm) 45+5 48+6 0.013
RA dilatation (x/3) 0 (0–0) 0 (0–1) 0.058
RV dilatation (x/3) 0 (0–1) 0 (0–1) 0.317
TR (x/4) 1 (0–1.5) 1 (1–2) 0.005
sPAP rest (mmHg) 27+6 28+7 0.427
Continuous variables are presented as mean+ standard deviation, discrete
variables as median (inter-quartile range).
For abbreviations, see Table 1.
Significant P-values (P, 0.05) are indicated in bold.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Bivariate correlation analysis with dynamic





RA dilatation at latest FU (x/3) 0.509 0.013
RA change during FU (Dx/3) 0.386 0.069
RV dilatation at latest FU (x/3) 20.100 0.658
RV change during FUa
TR severity at latest FU (x/4) 20.067 0.761
TR change during FU (Dx/4) 20.084 0.702
sPAP rest at latest FU (mmHg) 0.145
b
0.553
FU, follow-up. For the remaining abbreviations, see Table 1.
aRV dilatation did not change over time.
bPearson’s correlation coefficient.
Significant P-values (P, 0.05) are indicated in bold.
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Dynamic PVR in the combined group of
corrected ASD and SSc
Dynamic PVR in the combined group of corrected ASD and SSc
remained an independent predictor of PAH in multivariate analysis
(Table 5). Based on ROC curve analysis (AUC 0.856), a cut-off
value for dynamic PVR at 9.74 mmHg/L/min was determined as pre-
dictor for PAHdevelopment, with sensitivity and specificity of 63 and
93%, positive and negative predictive value of 0.67 and 0.92, respect-
ively (Figure 3). Positive and negative likelihood ratios were 9.33 and
0.40. This cut-off value was validated in the subgroup of SSc patients




velopment in patients with SSc, whereas dynamic PVR in corrected
ASDpatientswas associatedwith right heartmorphometric changes.
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Table 4 Cox regression analysis for PAH in patients
with SSc
Hazard ratio 95% CI P-value
Univariate analysis
Dynamic PVR 1.23 1.04–1.45 0.015
Age at latest FU 1.06 1.02–1.10 0.007
sPAP rest 1.15 1.07–1.24 ,0.001
sPAP peak exercise 1.13 1.07–1.20 ,0.001
Total PVR rest 1.25 0.99–1.56 0.054
Total PVR peak exercise 1.67 1.15–2.41 0.006
Gender 2.41 0.53–11.03 0.256
BMI 1.03 0.93–1.14 0.616
SBP rest 1.02 0.99–1.05 0.342
DBP rest 1.01 0.94–1.08 0.842
HR rest 1.01 0.97–1.06 0.587
Multivariate analysis
Dynamic PVR 1.22 1.01–1.47 0.038
Age at latest FU 1.00 0.95–1.06 0.933
sPAP rest 1.15 0.98–1.35 0.083
All variables refer to baseline measurements, unless otherwise specified.
PAH, pulmonary arterial hypertension; SSc, systemic sclerosis; CI, confidence
interval; PVR, pulmonary vascular resistance; FU, follow-up; sPAP, systolic
pulmonary artery pressure; BMI, bodymass index; SBP, systolic bloodpressure;DBP,
diastolic blood pressure; HR, heart rate
Figure1 Boxplot of dynamicPVRbyRAchangeduring follow-up
in patients with corrected ASD.
Figure 2 Mean dynamic PVR in patients with correctedASD and
SSc, differentiated by the development of PAH or RA change over
time.
Figure 3 Boxplot of dynamic PVR per disease type and the pres-
ence or absence of PAH or RA change during follow-up.
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The choice for dynamic PVR in the
prediction model
Right heart catheterization is the gold standard for PAH diagnosis.
However, non-invasive assessment techniques such as stress echo-
cardiography and cardiac magnetic resonance imaging are evolving
as useful tools for early PAH detection.8,27 Although the sensitivity
of transthoracic echocardiography at rest for early PAH diagnosis is
rather limited, stress echocardiography could be more promising
to predict PAH development through detection of mild PVD. In add-
ition, exercise capacity correlates with outcome in patients with
moderate to severe PAH.28
Our research group already developed a standardized technique
for the detection of mild PVD by bicycle stress echocardiography
(by measuring dynamic PVR) in patients with ASD and normal PAP
at rest.6 Some studies were able to show that PAP measurements
during rest and stress echocardiography correlated sufficiently well
with haemodynamic invasive measurements.7,17,29,30
Therefore, we focused more on dynamic PVR in our study.
We believe that dynamic PVR may better represent PVD than total
PVR at peak exercise.11 Dynamic PVR integrates more information
about patient haemodynamics (sPAP and cardiac output throughout
the entire exercise). Moreover, PVR at peak exercise is flow depend-
ent, whereas dynamic PVR is not.16 Furthermore, it is difficult to
measure sPAP at peak exercise instead of immediately after because
of the rapid decline during recovery.31 Dynamic PVRwill be less influ-
enced by delayed measurement. In addition, in a recently published
study of patients with SSc, sPAP at peak exercise was not predictive
of PAH development.24
Dynamic PVR: association with PAH and
right heart morphometric changes
In patients with corrected ASD, dynamic PVR was significantly asso-
ciated with RA dilatation at latest follow-up. Long-standing volume
overload of RV and pulmonary circulation in patients with secundum
ASD causes PVD in the long run.32 After late ASD closure, mild PVD
may even persist. We hypothesized that mild PVD, identified by
high-dynamic PVR, related to morphometric changes of the right
heart. We showed earlier that high PVR during exercise is related
to persistent TR after ASD closure.33 The present data fit with the
morphometric hypothesis. However, a longer follow-up time could
have showed greatermorphometric changes andmaybe PAHdevelop-
ment.34 No ASD patients developed PAH during follow-up. However,
high-dynamic PVR could be an early sign of PAH development, before
evidentRVremodellinghas takenplaceandsymptomsoccur.Moreover,
by excluding patients with a history of or current arrhythmias, wemight
have induced a selection bias. The risk of arrhythmia is indeed increased
in patients with late ASD closure, and this subgroup of ASD patients
could be at greater risk of PVD and PAH.
In contrast, no morphometric changes could be detected in SSc
patients, but PAH developed in 30%. This could be explained by the
rapid PAH development in SSc patients, probably before right heart
morphometric changes are observed.19 Dynamic PVR was identified
as an independent predictor of PAH development. Recent studies in
patients with SSc without clinically suspected PAH or elevated PAP
at rest analogously showed that an inappropriate PAP increase during
exercise was related to PAH development.10,24
Interestingly, Figure 2 showed that mean dynamic PVR in SSc
patients with PAH development and in corrected ASD patients
with RA change over time were within the same range. Moreover,
SSc patients without PAH and corrected ASD patients without RA
change during follow-up also presented similar mean dynamic PVR.
This suggests a different predictive value for dynamic PVR depending
on the underlying disease type. However, our data suggest that a
more severe underlying predisposing risk factor for PAH develop-
ment (connective tissue disease vs. shunt-related CHD) per se is
not enough to develop PAH, but that a certain degree of PVD, repre-
sented by a steeper dynamic PVR slope, is needed.
Future challenges
DynamicPVRaetiologycanbeconsideredmulticausal, includingdemo-
graphic variables (age, obesity, and physical health status), genetic
predisposition (gender), and environmental factors (pulmonary vascu-
lar overload and vasoconstriction, left ventricular dysfunction, and
pulmonary vascular distensibility).8,9,16,23,32,35–40 Therefore, clear
threshold values for exercise-induced PAP and dynamic PVR for the
prediction of PAH development are needed. The next step would be
the treatment of pathologically high dynamic PVR to prevent PAH
development and its (morphometric related) complications.41
Limitations
We simplified the way of slope calculation, which was based on two
measurement points (rest and peak exercise), to enable an equal
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Cox regression analysis for PAH in the





Dynamic PVR 1.35 1.14–1.60 0.001
Age at latest FU 1.07 1.02–1.11 0.003
Disease type 63.82 0.70–5798.61 0.071
sPAP rest 1.10 1.02–1.19 0.009
sPAP peak exercise 1.06 1.02–1.11 0.004




Gender 2.09 0.46–9.47 0.339
BMI 0.99 0.89–1.10 0.804
SBP rest 1.04 1.01–1.07 0.015
DBP rest 1.03 0.97–1.10 0.324
HR rest 1.05 1.00–1.09 0.034
Multivariate analysis
Dynamic PVR 1.44 1.01–2.05 0.045
Age at latest FU 1.02 0.91–1.14 0.768
sPAP rest 1.00 0.85–1.18 0.980
SBP rest 1.02 0.96–1.08 0.583
HR rest 1.09 0.95–1.25 0.237
All variables refer to baseline measurements, unless otherwise specified.
ASD, atrial septal defect. For the remaining abbreviations, see Table 4.
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slope calculation in both populations.Moremeasurement points per
patient, as methodologically examined earlier by our research
group,6 probably gives a more precise estimation of dynamic PVR.
However, multipoint sPAP-flow plots were well described by a
linear or slightly curvilinear approximation in earlier studies.16,31,42
In addition, there was a strong linear correlation between the
slopes of the corrected ASD group, measured with 2 vs. 5 measure-
ment points per patient (slope-2-points ¼ 1.26 × slope-5-points +
0.4; P, 0.001). Furthermore, echocardiographic measurements
were not confirmed by right heart catheterization. Therefore, it is
not excluded that somepatients had combinedprecapillary andpost-
capillary pulmonary hypertension. Moreover, analyses were limited
by the relatively small sample size, possibly resulting in a lack of
power. Lastly, no control groupwas implemented because of the dif-
ficulty tomatchwith both patientswith corrected ASD and SSc (lack
of homogeneity). For the corrected ASD group, data of a control
group are available.6
Conclusions
Dynamic PVR was identified as an important predictor for PAH de-
velopment in patientswith SSc,whereas dynamic PVRwas associated
withmorphometric changes of the right heart in patients after secun-
dum ASD closure. Dynamic PVR might have a different predictive
value depending on the underlying disease type or as a result of a dif-
ferent pace of disease progression in patients with SSc opposed to
corrected ASD. Larger studies are needed to confirm these findings
and to clearly define a diagnostic and prognostic relevant cut-off of
dynamic PVR.
Conflict of interest:None declared
Funding
This work was supported by a grant of the Agency for Innovation by
Science and Technology (IWT) in Flanders, Belgium [C.G.]. M.D. is sup-
ported by grants of the Companies Actelion, GlaxoSmithKline, Pfizer,
Bayer and United Therapeutics for research and consultancy in the
domain of pulmonary hypertension. W.B. and P.L. received a research
grant from Actelion Belgium. No funding resource was involved in the
study design, data collection and interpretation, writing, and submission
of the present study.
References
1. Galie` N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al. Guide-
lines for the diagnosis and treatment of pulmonary hypertension: the Task Force for
theDiagnosis andTreatmentof PulmonaryHypertensionof theEuropeanSocietyof
Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the
International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;
30:2493–537.
2. Yong G, Khairy P, De Guise P, Dore A, Marcotte F, Mercier LA et al. Pulmonary ar-
terial hypertension in patients with transcatheter closure of secundum atrial septal
defects: a longitudinal study. Circ Cardiovasc Interv 2009;2:455–62.
3. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a
description of six grades of structural changes in the pulmonary arteries with special
reference to congenital cardiac septal defects. Circulation 1958;18:533–47.
4. Lange SA, Braun MU, Schoen SP, Strasser RH. Latent pulmonary hypertension in
atrial septal defect: dynamic stress echocardiography reveals unapparent pulmonary
hypertension and confirms rapidnormalisation afterASDclosure.NethHeart J2013;
21:333–43.
5. Gru¨nig E, Janssen B, MerelesD, Barth U, Borst MM, Vogt IR et al.Abnormal pulmon-
ary artery pressure response in asymptomatic carriers of primary pulmonary hyper-
tension gene. Circulation 2000;102:1145–50.
6. VanDe Bruaene A, La Gerche A, Prior DL, Voigt JU, Delcroix M, BudtsW. Pulmon-
ary vascular resistance as assessed by bicycle stress echocardiography in patients
with atrial septal defect type secundum. Circ Cardiovasc Imaging 2011;4:237–45.
7. HimelmanRB, StulbargM,Kircher B, Lee E, Kee L,DeanNC et al.Noninvasive evalu-
ation of pulmonary artery pressure during exercise by saline-enhanced Doppler
echocardiography in chronic pulmonary disease. Circulation 1989;79:863–71.
8. Suzuki K, Akashi YJ, ManabeM,Mizukoshi K, Kamijima R, Kou S et al. Simple exercise
echocardiography using a Master’s two-step test for early detection of pulmonary
arterial hypertension. J Cardiol 2013;62:176–82.
9. Gru¨nig E, Weissmann S, Ehlken N, Fijalkowska A, Fischer C, Fourme T et al. Stress
Doppler echocardiography in relatives of patients with idiopathic and familial
pulmonary arterial hypertension: results of a multicenter European analysis of
pulmonary artery pressure response to exercise and hypoxia. Circulation 2009;
119:1747–57.
10. D’Alto M, Ghio S, D’Andrea A, Pazzano AS, Argiento P, Camporotondo R et al. In-
appropriate exercise-induced increase in pulmonary artery pressure in patientswith
systemic sclerosis. Heart 2011;97:112–7.
11. Huez S, Roufosse F, Vachie´ry JL, PavelescuA, DerumeauxG,Wautrecht JC et al. Iso-
lated right ventricular dysfunction in systemic sclerosis: latent pulmonary hyperten-
sion? Eur Respir J 2007;30:928–36.
12. CollinsN, Bastian B,Quiqueree L, Jones C, Morgan R, Reeves G. Abnormal pulmon-
ary vascular responses in patients registeredwith a systemic autoimmunity database:
Pulmonary Hypertension Assessment and Screening Evaluation using stress echo-
cardiography (PHASE-I). Eur J Echocardiogr 2006;7:439–46.
13. OelbergDA,Marcotte F, KreismanH,WolkoveN, LanglebenD, Small D. Evaluation
of right ventricular systolic pressure during incremental exercise by Doppler echo-
cardiography in adults with atrial septal defect. Chest 1998;113:1459–65.
14. Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. Exercise-
induced pulmonary arterial hypertension. Circulation 2008;118:2183–9.
15. Kovacs G, Maier R, Aberer E, Brodmann M, GraningerW, Kqiku X et al. Pulmonary
arterial hypertension therapy may be safe and effective in patients with systemic
sclerosis and borderline pulmonary artery pressure. Arthritis Rheum 2012;64:
1257–62.
16. Argiento P, Vanderpool RR, Mule` M, Russo MG, D’Alto M, Bossone E et al. Exercise
stress echocardiography of the pulmonary circulation: limits of normal and sex dif-
ferences. Chest 2012;142:1158–65.
17. Steen V, Chou M, Shanmugam V, Mathias M, Kuru T, Morrissey R. Exercise-induced
pulmonary arterial hypertension in patients with systemic sclerosis. Chest 2008;134:
146–51.
18. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T et al.
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical prac-
tice guidelines. Chest 2004;126:78S–92S.
19. Hsu VM,Chung L, Hummers LK,Wigley F, Simms R, BolsterM et al.Development of
pulmonary hypertension in a high-risk population with systemic sclerosis in the Pul-
monary Hypertension Assessment and Recognition of Outcomes in Scleroderma
(PHAROS) cohort study. Semin Arthritis Rheum 2014;44:55–62.
20. Kutty S, HazeemAA, BrownK, DanfordCJ,Worley SE, Delaney JW et al. Long-term
(5- to 20-year) outcomes after transcatheter or surgical treatment of hemodynam-
ically significant isolated secundum atrial septal defect. Am J Cardiol 2012;109:
1348–52.
21. Voilliot D, Magne J, Dulgheru R, Kou S, Henri C, Laaraibi S et al. Determinants of
exercise-induced pulmonary arterial hypertension in systemic sclerosis. Int J
Cardiol 2014;173:373–9.
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al.Recom-
mendations for chamber quantification. Eur J Echocardiogr 2006;7:79–108.
23. Ha JW, Choi D, Park S, Shim CY, Kim JM, Moon SH et al. Determinants of
exercise-induced pulmonary hypertension in patients with normal left ventricular
ejection fraction. Heart 2009;95:490–4.
24. Codullo V, Caporali R, Cuomo G, Ghio S, D’Alto M, Fusetti C et al. Stress Doppler
echocardiography in systemic sclerosis: evidence for a role in the prediction of pul-
monary hypertension. Arthritis Rheum 2013;65:2403–11.
25. Lancellotti P, Magne J, Donal E, O’Connor K, Dulgheru R, Rosca M et al. Determi-
nants and prognostic significance of exercise pulmonary hypertension in asymptom-
atic severe aortic stenosis. Circulation 2012;126:851–9.
26. Lancellotti P, TribouilloyC,HagendorffA, PopescuBA, EdvardsenT, PierardLA et al.
Recommendations for the echocardiographic assessment of native valvular regurgi-
tation: an executive summary from the European Association of Cardiovascular
Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611–44.
27. BadeschDB, ChampionHC, SanchezMA,HoeperMM, Loyd JE, Manes A et al.Diag-
nosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:
S55–66.
28. Oudiz RJ. The role of exercise testing in the management of pulmonary arterial
hypertension. Semin Respir Crit Care Med 2005;26:379–84.
29. Naeije R, Torbicki A.Moreon the noninvasive diagnosis of pulmonary hypertension:
Doppler echocardiography revisited. Eur Respir J 1995;8:1445–9.
Clinical significance of dynamic pulmonary vascular resistance 569
30. Freeman ML, Landolfo C, Safford RE, Keller CA, Heckman MG, Burger CD. Non-
invasive assessment of right heart function and hemodynamics during exercise in
patients with pulmonary arterial hypertension. South Med J 2013;106:141–6.
31. Argiento P, Chesler N, Mule` M, D’Alto M, Bossone E, Unger P et al. Exercise stress
echocardiography for the study of the pulmonary circulation. Eur Respir J 2010;35:
1273–8.
32. Jategaonkar S, ScholtzW, Schmidt H, Fassbender D, Horstkotte D. Cardiac remod-
eling and effects on exercise capacity after interventional closure of atrial septal
defects in different adult age groups. Clin Res Cardiol 2010;99:183–91.
33. De Meester P, Van De Bruaene A, Herijgers P, Voigt JU, Vanhees L, Budts W.
Increased pulmonary artery pressures during exercise are related to persistent tri-
cuspid regurgitation after atrial septal defect closure. Acta Cardiol 2013;68:365–72.
34. Gabriels C, De Meester P, Pasquet A, De Backer J, Paelinck BP, Morissens M et al. A
different view on predictors of pulmonary hypertension in secundum atrial septal
defect. Int J Cardiol 2014;176:833–40.
35. Mo¨ller T, Brun H, Fredriksen PM, Holmstrøm H, Peersen K, Pettersen E et al. Right
ventricular systolic pressure responseduring exercise in adolescents bornwith atrial
or ventricular septal defect. Am J Cardiol 2010;105:1610–6.
36. Mandegar M, Fung YC, HuangW, Remillard CV, Rubin LJ, Yuan JX. Cellular and mo-
lecular mechanisms of pulmonary vascular remodeling: role in the development of
pulmonary hypertension. Microvasc Res 2004;68:75–103.
37. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM.
Age-associated increases in pulmonary artery systolic pressure in the general popu-
lation. Circulation 2009;119:2663–70.
38. Sachweh JS, Daebritz SH, Hermanns B, Fausten B, Jockenhoevel S, Handt S et al.
Hypertensive pulmonary vascular disease in adults with secundum or sinus
venosus atrial septal defect. Ann Thorac Surg 2006;81:207–13.
39. McQuillan BM, PicardMH, Leavitt M,WeymanAE. Clinical correlates and reference
intervals for pulmonary artery systolic pressure among echocardiographically
normal subjects. Circulation 2001;104:2797–802.
40. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF. Range of
tricuspid regurgitation velocity at restandduring exercise innormal adultmen: impli-
cations for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 1999;33:
1662–6.
41. Van De Bruaene A, Jansen K, De Meester P, Delcroix M, Voigt JU, Gabriels C et al.
Bosentan for mild pulmonary vascular disease in Asd patients (the BOMPA
trial): a double-blind, randomized controlled, pilot trial. Int J Cardiol 2013;168:
5081–2.
42. Reeves J, Taylor A. Pulmonary Hemodynamics and Fluid Exchange in the Lungs During
Exercise. Lung Biology in Health and Disease. New York: Oxford University Press;
1996. p107–34.
IMAGE FOCUS
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
doi:10.1093/ehjci/jev016
Online publish-ahead-of-print 24 February 2015
Three-dimensional echocardiography guidance in case of papillary
fibroelastoma complicating transaortic valve implantation
Renuka Jain*, Tanvir Bajwa, Daniel O’Hair, and Bijoy K. Khandheria
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A 77-year-old man with severe aortic stenosis pre-
sented for transcatheter aortic valve replacement
(TAVR). His clinical history was significant for
severe chronic obstructive lung disease (COPD)
and prior treatment of lung cancer with surgery
and chest radiation. Given his co-morbidities and
frailty, he was classified as prohibitive risk for surgi-
cal aortic valve replacement. Given the anaesthesia
risks in the settingofCOPD, theplanwas for a trans-
esophageal echocardiogram (TEE) prior to implant-
ation in the cardiac catheterization laboratory.
On initial pre-procedure TEE images, a large
mobile echodensity was noted near the aortic
valve, with a stalk at the base of the non-coronary
cusp (Panel A, Supplementary data online, Videos
S1 and S2), the appearance most consistent with a
fibroelastoma. The decision wasmade to proceed with TAVR implantation, using 3-dimensional TEE guidance to avoid excessive manipu-
lation in the aortic root so there would be minimal disruption to the fibroelastoma. Under 3D TEE guidance, the wire was visualized as it
was advanced through the aortic valve (Panel B, Supplementary data online, Video S3). A Medtronic 31 mmCoreValve (Minneapolis, MN,
USA) was maneuvered into position and deployed with the valve ‘waist’ at the level of the fibroelastoma, essentially trapping the fibroe-
lastoma in the non-coronary cusp (Panel C, Supplementary data online, Video S4). It could be visualized with minimal mobility after TAVR
implantation. Minimal paravalvular regurgitation was noted (Panel D). The patient was uneventfully discharged 6 days later. This case illus-
trates the useof real-time 3-dimensional TEE to aid in a complex cardiac catheterizationprocedure treating both severe aortic stenosis and
a fibroelastoma in a patient who was not a surgical candidate.
Supplementary data are available at European Heart Journal – Cardiovascular Imaging online.
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